AAM
ARQT icon

Advisors Asset Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Advisors Asset Management’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.52M Buy
95,934
+16,818
+21% +$392K 0.04% 549
2026
Q1 		$1.86M Buy
79,116
+2,518
+3% +$64.3K 0.03% 622
2025
Q4 		$2.22M Buy
76,598
+29,366
+62% +$752K 0.04% 570
2025
Q3 		$890K Buy
47,232
+2,937
+7% +$46.3K 0.02% 822
2025
Q2 		$621K Buy
44,295
+16,108
+57% +$226K 0.01% 900
2025
Q1 		$441K Buy
28,187
+5,848
+26% +$82.4K 0.01% 962
2024
Q4 		$311K Buy
+22,339
New +$245K 0.01% 1036

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Advisors Asset Management's ARQT Position: Q2 2026 in Review

Advisors Asset Management increased its Arcutis Biotherapeutics (ARQT) stake by 21% in Q2 2026, buying an estimated $392K and bringing the position to 95,934 shares worth $2.52M. The position accounts for 0.04% of the portfolio, ranked #549.

Advisors Asset Management first reported a position in ARQT in Q4 2024 and has held it in 7 quarters since. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Advisors Asset Management held 95,934 shares of Arcutis Biotherapeutics worth $2.52M as of Q2 2026.
  • Advisors Asset Management bought 16,818 Arcutis Biotherapeutics shares in Q2 2026, an estimated $392K.
  • Arcutis Biotherapeutics made up 0.04% of Advisors Asset Management's portfolio in Q2 2026, its #549 holding.
  • Advisors Asset Management first reported a position in Arcutis Biotherapeutics in Q4 2024 and has held it in 7 quarters since.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Advisors Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.